Smart Nanoparticles Bust Tumor Fibrosis and Unlock Immune Attack on Cancer

Fibrosis — the pathological buildup of scar-like tissue — is a major driver of organ dysfunction and a primary reason many cancers resist immunotherapy. By physically excluding immune cells and creating immunosuppressive microenvironments, fibrotic tumors effectively hide from both the immune system and checkpoint-blocking drugs. Addressing this barrier has been a longstanding challenge in oncology and aging-related disease.

Researchers at Memorial Sloan Kettering Cancer Center identified P-selectin, a cell-surface adhesion molecule, as a distinguishing marker expressed by a specific subset of senescent-like cells residing within fibrotic tissues and tumors. Because senescent cells are highly heterogeneous, targeting the full population often produces off-target effects. P-selectin expression allowed the team to home in on the most disease-relevant subpopulation.

Leveraging the natural affinity of fucoidan — a sulfated polysaccharide — for P-selectin, the team engineered SMNPs (senescence-modulating nanoparticles) capable of selectively delivering therapeutic payloads to these pathogenic cells. In preclinical models, SMNPs demonstrated strong antifibrotic activity and favorably remodeled the immune landscape of tumors while maintaining an improved therapeutic index compared to systemic senolytic approaches.

Mechanistically, the team pinpointed a previously undercharacterized immunosuppressive macrophage population as a key functional target mediating the fibrotic and immune-exclusion phenotype. By neutralizing this population, SMNPs reopened the tumor microenvironment to cytotoxic immune infiltration. When combined with immune checkpoint inhibitors, fibrotic tumors that had been resistant became newly responsive.

The findings position SMNPs as a potentially generalizable platform — applicable not just in cancer but across fibrotic diseases of the lung, liver, and kidney where senescent cells drive pathology. Clinical translation will require validation in human trials, but the fucoidan-P-selectin targeting axis offers a compelling, biologically grounded entry point.